Vertex Pharmaceuticals (VRTX) Wells Fargo 20th Annual Healthcare Conference 2025 summary

Commercial execution and product launches

• Strong execution on three ongoing launches: Alyftrek (CF), Casgevy (sickle cell and beta thalassemia), and Journavx (acute pain), marking a new era of commercial diversification.

• Early Journavx launch shows promising uptake, with increasing payer coverage and hospital formulary adoption; expansion of sales force and targeted marketing planned as access broadens.

• Journavx prescriptions are split between at-home post-surgical care and hospital/ASC settings, with notable uptake among dentists and a broad range of prescribers.

• Repeat prescriptions and positive physician and patient feedback indicate strong early momentum for Journavx.

• Expansion into new geographies and younger patient populations continues to drive CF franchise growth, with Alyftrek and Trikafta conversions ongoing.

Regulatory and clinical development updates

• Regulatory discussions with the FDA clarified that a broad peripheral neuropathic pain label is not yet attainable; focus shifted to two phase III DPN studies as anchor for future label expansion.

• Both DPN phase III trials are expected to complete enrollment in 2026, with trial design leveraging well-trained sites to maximize probability of success.

• VX-993 will not advance as monotherapy in acute pain due to lack of additional benefit over Journavx, but remains in DPN studies and as a potential combination candidate.

• Serial innovation in pain is expected to focus on NaV1.7 inhibition and potential combination therapies for synergistic effects.

Pipeline and future growth drivers

• Four ongoing phase III studies and a fifth to start soon, spanning kidney diseases (Inaxaplin for APOL1-mediated kidney disease, Pove for IgA nephropathy), type 1 diabetes (zimslecel), and peripheral neuropathic pain.

• Pove phase III in IgA nephropathy aims for best-in-class B-cell control, with interim analysis data expected in the first half of 2026 and full enrollment by year-end.

• Inaxaplin phase III for APOL1-mediated kidney disease is on track for interim analysis cohort enrollment by year-end, with data possible in 2025 or early 2027.

• Additional proof-of-concept studies underway in myotonic dystrophy type 1 (VX-670) and ADPKD (VX-407), with enrollment and dosing milestones expected in 2026.

• Expansion of Pove into additional indications, including primary membranous nephropathy, WAIHA, and generalized myasthenia gravis, with new phase III studies and regulatory discussions planned.